Poseida Therapeutics, Inc. (NASDAQ:PSTX) to Post FY2022 Earnings of ($2.94) Per Share, Cantor Fitzgerald Forecasts

Poseida Therapeutics, Inc. (NASDAQ:PSTX) – Cantor Fitzgerald decreased their FY2022 earnings per share (EPS) estimates for Poseida Therapeutics in a report released on Wednesday, January 12th. Cantor Fitzgerald analyst B. Cheng now forecasts that the company will earn ($2.94) per share for the year, down from their previous forecast of ($2.88). Cantor Fitzgerald currently has a “Overweight” rating and a $24.00 target price on the stock.

Other research analysts have also issued research reports about the company. Zacks Investment Research lowered Poseida Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Piper Sandler increased their price objective on Poseida Therapeutics from $17.00 to $19.00 and gave the company an “overweight” rating in a report on Tuesday, October 12th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Poseida Therapeutics currently has a consensus rating of “Buy” and an average price target of $22.69.

Shares of PSTX stock opened at $5.26 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 6.44 and a quick ratio of 6.44. The firm has a market cap of $328.78 million, a P/E ratio of -2.01 and a beta of -0.57. The stock’s 50-day moving average is $6.85 and its two-hundred day moving average is $7.63. Poseida Therapeutics has a fifty-two week low of $4.93 and a fifty-two week high of $13.64.

Poseida Therapeutics (NASDAQ:PSTX) last issued its earnings results on Tuesday, November 9th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.06.

Several hedge funds have recently made changes to their positions in PSTX. Russell Investments Group Ltd. lifted its position in shares of Poseida Therapeutics by 157.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 39,127 shares of the company’s stock worth $391,000 after acquiring an additional 23,939 shares during the period. Rhumbline Advisers lifted its position in shares of Poseida Therapeutics by 37.5% in the 2nd quarter. Rhumbline Advisers now owns 30,461 shares of the company’s stock worth $305,000 after acquiring an additional 8,301 shares during the period. Citigroup Inc. lifted its position in shares of Poseida Therapeutics by 76.0% in the 2nd quarter. Citigroup Inc. now owns 5,937 shares of the company’s stock worth $59,000 after acquiring an additional 2,564 shares during the period. Virtus ETF Advisers LLC bought a new stake in shares of Poseida Therapeutics in the 2nd quarter worth approximately $243,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Poseida Therapeutics by 31.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 82,900 shares of the company’s stock worth $830,000 after acquiring an additional 19,800 shares during the period. Institutional investors own 41.84% of the company’s stock.

In other Poseida Therapeutics news, Director Life Sciences Holdings L. Malin bought 71,312 shares of the firm’s stock in a transaction that occurred on Thursday, November 18th. The stock was purchased at an average price of $7.18 per share, for a total transaction of $512,020.16. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Eric Ostertag sold 18,924 shares of the stock in a transaction that occurred on Monday, November 8th. The shares were sold at an average price of $7.09, for a total value of $134,171.16. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 174,118 shares of company stock valued at $1,223,673. 44.00% of the stock is owned by corporate insiders.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC.

Featured Article: CBOE Russell 2000® Volatility Index

Earnings History and Estimates for Poseida Therapeutics (NASDAQ:PSTX)

Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.